A citation-based method for searching scientific literature

Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing, C David Sjöström, Roberto D Toto, Anna-Maria Langkilde, David C Wheeler. N Engl J Med 2020
Times Cited: 370



Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. N Engl J Med 2015
Times Cited: 4839




List of shared articles



Times cited

Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, David R Matthews, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Jaime Blais, Qiang Li, Meg J Jardine,[...]. Am J Kidney Dis 2021
3

Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
Victor Okunrintemi, Basem M Mishriky, James R Powell, Doyle M Cummings. Diabetes Obes Metab 2021
6

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Pardeep S Jhund, Scott D Solomon, Kieran F Docherty, Hiddo J L Heerspink, Inder S Anand, Michael Böhm, Vijay Chopra, Rudolf A de Boer, Akshay S Desai, Junbo Ge,[...]. Circulation 2021
31

Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
Brendon L Neuen, Clare Arnott, Vlado Perkovic, Gemma Figtree, Dick de Zeeuw, Greg Fulcher, Min Jun, Meg J Jardine, Sophia Zoungas, Carol Pollock,[...]. Diabetes Obes Metab 2021
13

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced.
Faiez Zannad, João Pedro Ferreira, Stuart J Pocock, Cordula Zeller, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Sibylle Jenny Hauske, Martina Brueckmann, Egon Pfarr,[...]. Circulation 2021
17

Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).
Eun Sil Koh, Kyungdo Han, You-Seon Nam, Eric T Wittbrodt, Peter Fenici, Mikhail N Kosiborod, Hiddo J L Heerspink, Soon-Jib Yoo, Hyuk-Sang Kwon. Diabetes Obes Metab 2021
3

TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Parminder K Judge, Richard Haynes. Curr Opin Nephrol Hypertens 2021
0

Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations.
Chin Meng Khoo, Chaicharn Deerochanawong, Siew Pheng Chan, Bien Matawaran, Wayne Huey-Herng Sheu, Juliana Chan, Ambrish Mithal, Andrea Luk, Ketut Suastika, Kun-Ho Yoon,[...]. Diabetes Obes Metab 2021
2

Organ protection beyond glycaemic control with SGLT2 inhibitors.
Usha Panchapakesan, Carol Pollock. Nat Rev Nephrol 2021
0

Guideline recommendations and the positioning of newer drugs in type 2 diabetes care.
Nikolaus Marx, Melanie J Davies, Peter J Grant, Chantal Mathieu, John R Petrie, Francesco Cosentino, John B Buse. Lancet Diabetes Endocrinol 2021
10

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease.
John J V McMurray, David C Wheeler, Bergur V Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Claes Held, Fan-Fan Hou,[...]. Circulation 2021
11

Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes.
Ronald M Goldenberg, Vineeta Ahooja, Kristin K Clemens, Jeremy D Gilbert, Megha Poddar, Subodh Verma. Can J Diabetes 2021
1

Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function.
Volker Vallon, Subodh Verma. Annu Rev Physiol 2021
7

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
83

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
141

Metabolic Consequences of Solid Organ Transplantation.
Mamatha Bhat, Shirine E Usmani, Amirhossein Azhie, Minna Woo. Endocr Rev 2021
0

Circadian Variation and Arterial Stiffness in Chronic Kidney Disease and Their Treatment.
Satoshi Hoshide, Daisuke Suzuki, Kazuomi Kario. Am J Hypertens 2021
2

How Diabetes and Heart Failure Modulate Each Other and Condition Management.
Varinder Kaur Randhawa, Savita Dhanvantari, Kim A Connelly. Can J Cardiol 2021
0

Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials.
Giovanni Antonio Silverii, Matteo Monami, Edoardo Mannucci. Diabetes Obes Metab 2021
3

Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial.
Rosalie A Scholtes, Marcel H A Muskiet, Michiel J B van Baar, Anne C Hesp, Peter J Greasley, Cecilia Karlsson, Ann Hammarstedt, Niki Arya, Daniël H van Raalte, Hiddo J L Heerspink. Diabetes Care 2021
12

Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
Mikhail Kosiborod, Otavio Berwanger, Gary G Koch, Felipe Martinez, Omar Mukhtar, Subodh Verma, Vijay Chopra, Ali Javaheri, Philip Ambery, Samvel B Gasparyan,[...]. Diabetes Obes Metab 2021
8


Latin American Expert Consensus for Comprehensive Management of Type 2 Diabetes from a Metabolic-Cardio-Renal Perspective for the Primary Care Physician.
Roopa Mehta, Daniel Pichel, Chih Hao Chen-Ku, Pablo Raffaele, Antonio Méndez Durán, Francisco Padilla, Jose Javier Arango Alvarez, José Esteban Costa Gil, Juan Esteban Gómez Mesa, Mariano Giorgi,[...]. Diabetes Ther 2021
0


SGLT2 inhibitors: expanding their Empire beyond diabetes.
Marcel H A Muskiet, Hiddo J L Heerspink, Daniël H van Raalte. Lancet Diabetes Endocrinol 2021
1

Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction.
Rio P Juni, Rushd Al-Shama, Diederik W D Kuster, Jolanda van der Velden, Henrike M Hamer, Marc G Vervloet, Etto C Eringa, Pieter Koolwijk, Victor W M van Hinsbergh. Kidney Int 2021
3

The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease.
Filipe Ferrari, Vítor M Martins, Rafael S Scheffel, Anderson D da Silveira, Marcelo Trotte Motta, Emilio H Moriguchi, Raul D Santos, Ricardo Stein. Ann Pharmacother 2021
0

Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.
Ravi B Patel, Jozine M Ter Maaten, João Pedro Ferreira, Finnian R McCausland, Sanjiv J Shah, Patrick Rossignol, Scott D Solomon, Muthiah Vaduganathan, Milton Packer, Aliza Thompson,[...]. Circulation 2021
2

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.
Takayuki Yamada, Mako Wakabayashi, Abhinav Bhalla, Nitin Chopra, Hirotaka Miyashita, Takahisa Mikami, Hiroki Ueyama, Tomohiro Fujisaki, Yusuke Saigusa, Takahiro Yamaji,[...]. Cardiovasc Diabetol 2021
2

Relationship between basal sodium intake and the effects of dapagliflozin in albuminuric diabetic kidney disease.
Sho Kinguchi, Hiromichi Wakui, Yuzuru Ito, Yoshinobu Kondo, Kengo Azushima, Uru Osada, Tadashi Yamakawa, Tamio Iwamoto, Jun Yutoh, Toshihiro Misumi,[...]. Sci Rep 2021
0

2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee.
Thomas M Maddox, James L Januzzi, Larry A Allen, Khadijah Breathett, Javed Butler, Leslie L Davis, Gregg C Fonarow, Nasrien E Ibrahim, JoAnn Lindenfeld, Frederick A Masoudi,[...]. J Am Coll Cardiol 2021
38

Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches.
Philip Düsing, Andreas Zietzer, Philip Roger Goody, Mohammed Rabiul Hosen, Christian Kurts, Georg Nickenig, Felix Jansen. J Mol Med (Berl) 2021
1



Treatment of Diabetic Kidney Disease: Current and Future.
Tomotaka Yamazaki, Imari Mimura, Tetsuhiro Tanaka, Masaomi Nangaku. Diabetes Metab J 2021
4

Gliflozins for the Treatment of Congestive Heart Failure and Renal Failure in Type 2 Diabetes.
Anna Katharina Seoudy, Dominik M Schulte, Tim Hollstein, Ruwen Böhm, Ingolf Cascorbi, Matthias Laudes. Dtsch Arztebl Int 2021
3

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors.
Ralph A DeFronzo, W Brian Reeves, Alaa S Awad. Nat Rev Nephrol 2021
10

Update on diagnosis, pathophysiology, and management of diabetic kidney disease.
Mai Sugahara, Wai Lun Will Pak, Tetsuhiro Tanaka, Sydney C W Tang, Masaomi Nangaku. Nephrology (Carlton) 2021
3

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial.
Nan Ye, Meg J Jardine, Megumi Oshima, Carinna Hockham, Hiddo J L Heerspink, Rajiv Agarwal, George Bakris, Aletta E Schutte, Clare Arnott, Tara I Chang,[...]. Circulation 2021
4



Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.
Biff F Palmer, Deborah J Clegg. Clin J Am Soc Nephrol 2021
1


Diabetes, gender and deterioration in estimated glomerular filtration rate in patients with chronic heart failure: Ten-year prospective cohort study.
Jessica Kearney, Michael Drozd, Andrew Mn Walker, Thomas A Slater, Sam Straw, John Gierula, Maria Paton, Judith Lowry, Charlotte Cole, Klaus K Witte,[...]. Diab Vasc Dis Res 2021
0

Effect of Dapagliflozin on Urine Metabolome in Patients with Type 2 Diabetes.
Evdoxia Bletsa, Sebastien Filippas-Dekouan, Christina Kostara, Panagiotis Dafopoulos, Aikaterini Dimou, Eleni Pappa, Styliani Chasapi, Georgios Spyroulias, Anastasios Koutsovasilis, Eleni Bairaktari,[...]. J Clin Endocrinol Metab 2021
1

Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
Peter M Becher, Benedikt Schrage, Giulia Ferrannini, Lina Benson, Javed Butler, Juan Jesus Carrero, Francesco Cosentino, Ulf Dahlström, Linda Mellbin, Giuseppe M C Rosano,[...]. Eur J Heart Fail 2021
3



Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
Kirtipal Bhatia, Vardhmaan Jain, Kartik Gupta, Agam Bansal, Arieh Fox, Arman Qamar, Kevin Damman, Muthiah Vaduganathan. Eur J Heart Fail 2021
3

SGLT2 inhibitors and cardiovascular and renal outcomes: a meta-analysis and trial sequential analysis.
Mahmoud Barbarawi, Ahmad Al-Abdouh, Owais Barbarawi, Harini Lakshman, Mariam Al Kasasbeh, Kai Chen. Heart Fail Rev 2021
3